Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review.
Monach
Paul A
PA
Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts 02118, USA. pmonach@bu.edu
Arnold
Lindsay M
LM
Merkel
Peter A
PA
D018501:Antirheumatic Agents / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000009:adverse effects* / Q000037:antagonists & inhibitors; D003556:Cystitis / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control; D016206:Databases, Bibliographic; D006801:Humans; D015994:Incidence; D015080:Mesna / Q000494:pharmacology*; D020011:Protective Agents / Q000494:pharmacology*; D012216:Rheumatic Diseases / Q000188:drug therapy*; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control
D018501:Antirheumatic Agents; D020011:Protective Agents; D003520:Cyclophosphamide; D015080:Mesna